Universal Registration Document

Overview

The report describes the company as a clinical-stage gene-therapy developer focused on severe retinal neurodegenerative diseases, with LUMEVOQ and GS030 as its lead candidates. It reports 2,582 thousand euros of consolidated revenue and 46 full-time employees at December 31, 2022. After year-end, the company withdrew its European marketing application for LUMEVOQ and began assessing next steps. Environmental disclosures describe electronic document management, double-sided printing and purchasing EU Ecolabel or PEFC paper.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Publication date: 10 May 2023
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services